Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients

Abstract

The systemic inflammation response index (SIRI) is a useful tool for predicting prognosis in some types of cancer. In this retrospective study, we evaluated the efficacy of SIRI in predicting overall survival in hepatocellular carcinoma (HCC) patients following local or systemic therapy. A cutoff value of 1.05 was identified for SIRI using ROC analysis in a training patient cohort. In the validation cohort, survival analysis revealed that median overall survival was longer in HCC patients with SIRI scores < 1.05 than in those with scores ≥ 1.05. Cox analysis of the validation cohort demonstrated that SIRI was associated with overall survival and was more predictive of overall survival that the AFP level or Child-Pugh score. However, SIRI and Barcelona Clinic Liver Cancer (BCLC) stage were equally effective for predicting survival. In addition, HCC patients with BCLC stage C had higher SIRI scores and poorer overall survival. SIRI also correlated with liver function parameters. Thus SIRI may be a convenient, low cost and reliable tumor marker for predicting prognosis in HCC patients.

Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer

“…We agree with Qi et al that incorporating the prognostic value added by each leukocyte count creates an even more integrative biomarker than analyzing the individual counts. A limited number of studies have been published analyzing the prognostic capacity of SIRI . To the best of our knowledge, this is the first study analyzing SIRI as a prognostic factor in a large series of OSCC.…”

“…A limited number of studies have been published analyzing the prognostic capacity of SIRI. [27][28][29][30][31] To the best of our knowledge, this is the first study analyzing SIRI as a prognostic factor in a large series of OSCC.…”

Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score‐matching study

“…This scoring system was established to reflect patients' systemic inflammatory response and sensitivity to chemotherapeutic agents . Since its first introduction onto prognostic prediction, the clinical significance of SIRI has been validated across a variety of malignancies …”

“…Recently, a novel inflammatory indicator comprising continuous variables of peripheral neutrophil, lymphocyte and monocyte counts, termed systemic inflammation response index (SIRI), was first developed on patients receiving chemotherapy for advanced pancreatic cancer, showing a potent prognostic significance . SIRI was then reported to be an excellent predictor for long‐term survival of patients with oesophageal squamous cell carcinoma, gastric adenocarcinoma and renal cell carcinoma . However, until recently, there has been no study addressing on clinical significance of SIRI for either short‐term or long‐term outcome following lung cancer surgery.…”

“…5 SIRI was then reported to be an excellent predictor for long-term survival of patients with oesophageal squamous cell carcinoma, gastric adenocarcinoma and renal cell carcinoma. [6][7][8][9] However, until recently, there has been no study addressing on clinical significance of SIRI for either short-term or long-term outcome following lung cancer surgery.…”